8,265 reports of this reaction
3.6% of all TERIPARATIDE reports
#4 most reported adverse reaction
DIZZINESS is the #4 most commonly reported adverse reaction for TERIPARATIDE, manufactured by Eli Lilly and Company. There are 8,265 FDA adverse event reports linking TERIPARATIDE to DIZZINESS. This represents approximately 3.6% of all 227,333 adverse event reports for this drug.
TERIPARATIDE has an overall safety score of 78 out of 100. Patients taking TERIPARATIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among TERIPARATIDE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for TERIPARATIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 8,265 FDA reports for TERIPARATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.6% of all adverse event reports for TERIPARATIDE, making it a notable side effect.
If you experience dizziness while taking TERIPARATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.